1309666-78-1

Usage

Uses

Used in Chemical Synthesis:
Tos-PEG2-t-butyl ester is used as a protecting group in chemical synthesis for carboxyl-containing compounds. The t-butyl ester provides a stable and easily removable protection under acidic conditions, facilitating the synthesis of complex molecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Tos-PEG2-t-butyl ester is used as a component in drug delivery systems. The hydrophilic PEG spacer enhances the solubility and stability of drug molecules in aqueous environments, while the t-butyl ester allows for controlled release of the active pharmaceutical ingredient under specific conditions.
Used in Bioconjugation:
Tos-PEG2-t-butyl ester is utilized as a linker in bioconjugation processes. The tosyl group's reactivity in nucleophilic substitution reactions enables the efficient attachment of various biomolecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces for applications in diagnostics, therapeutics, and research.
Used in Surface Modification:
In materials science, Tos-PEG2-t-butyl ester is used for surface modification of various substrates. The PEG spacer can improve the hydrophilicity and biocompatibility of surfaces, making it suitable for applications in medical devices, sensors, and other technologies where surface properties are crucial.

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 671802-00-9 3-(2-hydroxyethoxy)propionic acid tert-butyl ester 
• 1663-39-4 tert-Butyl acrylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1309666-79-2 C₄₄H₅₂O₈ 
• 1260092-46-3 3-(2-aminoethoxy)propionic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis of Cyclic and Acyclic Nucleoside Phosphonates and Sulfonamides Derived from 6-(Thiophen-2-yl)-7-fluoro-7-deazapurine

Ribonuclosides derived from 6-hetaryl-7-dezapurines are potent cytostatics, but their mechanism of action is unknown. Here we designed and synthesized a series of cyclic and acyclic nucleoside phosphonates, as well as carboxy, cyano, sulfo, and sulfonamide acyclic analogues derived from 6-thiophen-2-yl-7-deazapurine and 7-fluoro-6-thiophen-2-yl-7-deazapurine as ribonucleoside monophosphate mimics. None of these analogues exerted significant cytotoxic and antiviral activity.

LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders

Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

Compound for targeted ubiquitination degradation of ERRalpha protein and pharmaceutical composition and application thereof

The invention provides a compound with a structure shown as a formula (I), which has the effects of inhibiting ERRalpha protein activity and degrading ERRalpha protein activity, has relatively strongsubtype selectivity and can also effectively inhibit tri

Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

BIHETEROCYCLIC COMPOUND

The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X═Y—Z, X—Y═Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Fluorometric sensing of biogenic amines with aggregation-induced emission-active tetraphenylethenes

A fluorometric sensor for detection and identification of biogenic amines with carboxylic acid modified tetraphenylethenes (TPEs) based on aggregation-induced emission (AIE) is reported. A mixture of the carboxylic acid substituted TPE and biogenic amines